SynthesisEuropean respiratory review : an official journal of the European Respiratory Society2026
Global herpes zoster burden in adults with COPD: a systematic review and meta-analysis.
Synthesis in European respiratory review : an official journal of the European Respiratory Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOPD is associated with an increased risk of infections, such as herpes zoster, potentially leading to greater morbidity and mortality. This systematic review assessed the evidence on herpes zoster burden in COPD.
methodsA global systematic literature review and meta-analysis was conducted (MEDLINE/Embase, 2003-2024) on herpes zoster burden (incidence, risk, complications, impact on COPD and healthcare resources) in adults aged ≥18 years with COPD.
results22 studies on herpes zoster burden in COPD were included. The pooled herpes zoster incidence rate per 1000 person-years in adults with COPD aged ≥18 years was 10.98 (95% CI 8.28-14.56), increasing to 13.95 (10.80-18.02) in adults aged ≥50 years. The pooled risk ratio of developing herpes zoster was 1.49 (1.17-1.89) in adults aged ≥18 years with COPD and 1.86 (1.28-2.69) in COPD treated with corticosteroids. The pooled rate ratio of developing post-herpetic neuralgia (persistent pain lasting ≥90 days) was 1.50 (1.10-2.04) in adults with herpes zoster and COPD
conclusionsAdults with COPD have an increased risk of herpes zoster and complications and an associated burden on healthcare systems, with higher risks in those on corticosteroids. Herpes zoster vaccines offer effective protection, including for adults with COPD, and could help reduce the disease and its economic burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.